Clinical Trials Logo
  1. Home
  2. Endocarditis, Bacterial
  3. NCT00524212
  4. Details
NCT00524212 Clinical Trial

How to Improve Diagnosis in Infective Endocarditis

Endocarditis, Bacterial Clinical Trial

Official title:
Ph. D Student, Jane Byriel Knudsen, Aarhus University

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00524212
Other study ID # 06-10-B640-A1205-22345
Secondary ID 20060181SUN-2007
Status Completed
Phase N/A
First received August 31, 2007
Last updated January 19, 2010
Start date March 2007
Est. completion date May 2009

Study information
Verified date January 2010
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: Ethics CommitteeDenmark: Danish Dataprotection Agency
Study type Observational

Clinical Trial Summary

The purpose is to exam prospective if simple clinical information in combination with a normal s-procalcitonin are sufficient for exclusion of infective endocarditis (IE).

Description:

Despite progress in surgical and medical treatment, infective endocarditis is still associated with high morbidity and mortality.

The variable clinical presentation of IE makes the diagnosis a clinical challenge.

Procalcitonin is a precursor from the hormone calcitonin and also a marker of systemic bacterial infections.

The purpose of this study is:

- to investigate the diagnostic value of serum procalcitonin (PCT), C-reactive protein (CRP) and sedimentation rate (SR) when IE is suspected.

- to investigate if a retrospectively generated clinical model suitable for exclusion of IE can be confirmed prospectively.

Recruitment information / eligibility
Status Completed
Enrollment 761
Est. completion date May 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients > or = 18 year with suspected or verified Infective Endocarditis

- By word of mouth or in writing consent

Exclusion Criteria:

- Incapacity

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Denmark Department of Cardiology, Aarhus University Hospital Aarhus

Sponsors (1)
Lead Sponsor Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

See also
  Status Clinical Trial Phase
Terminated NCT00401960 - Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. Phase 4
Terminated NCT00695903 - Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Phase 2
Recruiting NCT05644990 - T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Recruiting NCT04840225 - Anemia in Patients With Endocarditis
Completed NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Completed NCT00144885 - IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis N/A
Completed NCT03306225 - Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
Active, not recruiting NCT05522764 - Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Terminated NCT04222257 - Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Phase 4
Not yet recruiting NCT05152225 - Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study
Not yet recruiting NCT05613933 - Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis N/A
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Active, not recruiting NCT06434012 - Barts Endocarditis Research Registry
Recruiting NCT06250985 - New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System Phase 3